Cardiotoxicity from covalent kinase inhibitors explained
Official title: Mechanisms of Cardiotoxicity Associated with Covalent Kinase Inhibitors
Funded at Stanford University · NIH-11415073 · Data updated 2026-11-12
A Stanford team is studying why certain cancer drugs (kinase inhibitors) can harm the heart, so doctors can prevent and manage these effects in patients.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project start | September 1, 2019 |
| Project end | August 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $790,566 |
| NIH project number | 5P01HL141084-08 |
| Project ID | NIH-11415073 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients treated with covalent kinase inhibitors or those with cardiotoxicity reports could benefit from findings, especially those at risk for atrial fibrillation.
✕Less likely to help
This research does not involve enrolling patients directly; it uses pre-clinical models and retrospective clinical data to understand toxicity.
What this research studies
This project creates pre-clinical models to understand how covalent kinase inhibitors cause heart problems, especially arrhythmias like atrial fibrillation. It uses cell-based tests and genetically engineered tools to identify off-target kinases, such as CSK, that may drive toxicity. Mouse studies will test remodeling and electrophysiologic changes, while clinical data will help validate findings in patients. The goal is to connect laboratory mechanisms to real-world patient risk and guide safer use of these drugs.
Why it matters
Potential benefit: If successful, the work could lead to safer cancer therapies with fewer heart-related side effects.
How similar studies have gone: Previous work in kinase inhibitors has linked off-target effects to cardiotoxicity, but dedicated pre-clinical models for covalent inhibitors are still being refined.
Where this research is happening
-
Stanford University
Stanford, United States Active
Researchers
- Principal investigator: Wu, Joseph C. — Stanford University
- Study coordinator: Wu, Joseph C.
Related research
Other NIH-funded projects on the same topics.
-
Dual targeting of heart cell receptors to prevent chemotherapy heart damage
Atrial patients receiving the chemotherapy drug doxorubicin may be protected from heart damage by targeting two heart cell receptors at once.
-
Genetic clues for doxorubicin heart risk using patient-derived heart cells
A research project tests how human heart cells grown from stem cells react to a common chemotherapy to see which genetic differences may raise the risk of heart damage.
-
Targeting STK3 to protect the heart during breast cancer treatment
A new approach tests whether blocking STK3 can protect the heart from chemotherapy damage without reducing its cancer-fighting effect in breast cancer patients.
-
High-throughput 3D human heart tissue to screen drug safety
A Johns Hopkins team is creating a high-throughput, 3D human heart tissue model to test drug safety on human heart cells.
-
Precision imaging of heart damage from cancer treatment using metabolic MRI biomarkers
Researchers will use advanced MRI to find early metabolic signs of heart injury in cancer patients treated with common drugs, so doctors can protect the heart earlier.
-
PET imaging to detect heart damage from chemotherapy
This research tests a new PET imaging tracer to detect early heart muscle damage in people who have received cancer chemotherapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.